Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jacobio Pharmaceuticals Group Co Debt-to-Equity?
Jacobio Pharmaceuticals Group CoJBPHF 32 Debt-to-Equity is 0.21 as of Dec. 2025, which is 250% above its 10-year median of 0.06. GuruFocus rates JBPHF with a GF Score™ of 32/100 and a GF Value™ of $0.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 965 Biotechnology companies, Jacobio Pharmaceuticals Group Co ranks worse than 55.85% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's Debt-to-Equity or its related term are showing as below:
JBPHF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.16 Med: 0.06 Max: 0.21
Current: 0.21
During the past 8 years, the highest Debt-to-Equity Ratio of Jacobio Pharmaceuticals Group Co was 0.21. The lowest was -0.16. And the median was 0.06.
JBPHF's Debt-to-Equity is ranked worse than 55.85% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs JBPHF: 0.21
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Jacobio Pharmaceuticals Group Co Debt-to-Equity Related Terms
Jacobio Pharmaceuticals Group Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Debt-to-Equity Chart
JBPHF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (JBPHF) has a Debt-to-Equity of 0.21 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. This is 250% above median its historical median of 0.06. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #539 out of 965 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Jacobio Pharmaceuticals Group Co's Debt-to-Equity too high?
Jacobio Pharmaceuticals Group Co's current Debt-to-Equity of 0.21 is 250% above median its 10-year median of 0.06. The Biotechnology industry median Debt-to-Equity is 0.16. Jacobio Pharmaceuticals Group Co's value of 0.21 is 31.3% above this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #539 out of 965 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #539 out of 965 companies for Debt-to-Equity. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Jacobio Pharmaceuticals Group Co's value of 0.21 is 31.3% above this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.16, Jacobio Pharmaceuticals Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current Debt-to-Equity of 0.21 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current Debt-to-Equity is 0.21, which is 250% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (JBPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.30, compared to a current price of $0.64 — trading 113.4% above its estimated fair value. The current Debt-to-Equity is 0.21, which is 250% above median its 10-year median of 0.06 and 31.3% above the Biotechnology industry median of 0.16. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Debt-to-Equity is 0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.64 is trading 113.4% above its estimated GF Value™ of $0.30.
GuruFocus considers Jacobio Pharmaceuticals Group Co to be Significantly Overvalued.
Key valuation signals for JBPHF:
Debt-to-Equity: 0.21 (250% above median its 10-year median of 0.06)
GF Value™: $0.30 vs. price of $0.64 (113.4% above fair value)
Industry Position: 31.3% above the Biotechnology median (#539 of 965)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
32GF Score
Get the complete analysis for JBPHF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
